[PLACEHOLDER] On mechanism-class mapping in oncology deal flow
Why grouping deals by indication understates the structural shift toward antibody-drug conjugates and radioligand therapy — and what a cleaner taxonomy reveals.
12 Apr 2026 · 8 min
Buyside research and qualified-counterparty introductions in life sciences.
[PLACEHOLDER] A Swiss research practice serving institutional principals — disciplined sector coverage, no retail intermediation, intuitu personae engagements.
Drag to rotate · hover to inspect
Research
[PLACEHOLDER] Original sector coverage with an institutional standard of care. Mechanism-class mapping, deal-flow tracking, competitive landscapes — produced for principals who require evidence, not narrative.
Introductions
[PLACEHOLDER] Qualified-counterparty introductions on an intuitu personae basis. Restricted to institutional principals, family offices, and strategic industrials. No retail intermediation, no fund handling.
Diligence support
[PLACEHOLDER] Targeted support across the diligence arc: scientific review, transaction-comparable benchmarking, mechanism-class triangulation. Engagement-defined scope, not a productized retainer.
Tools
A live tracker of life-sciences deal flow.
[PLACEHOLDER caption] A continuously updated view of mechanism-class deal flow, partnership structures, and counterparty patterns.
Methodology
Recent notes.
[PLACEHOLDER] Counterparty quality is not counterparty size
The conventional proxies for institutional quality — fund AUM, portfolio breadth, brand — collapse as predictors when the engagement is intuitu personae.
03 Mar 2026 · 5 min
[PLACEHOLDER] Why Swiss jurisdiction, and what it constrains
FINMA's perimeter is narrower than most foreign principals assume — but the constraints it does impose materially shape what a research practice can offer.
09 Feb 2026 · 6 min
For substantive enquiries: contact@tili.ch